Recruiting

Observational Study

Sponsor:

Astellas Gene Therapies

Code:

NCT06581146

Conditions

X-Linked Myotubular Myopathy

Eligibility Criteria

Sex: Male

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

No Intervention

Study Details

Brief summary:

XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.

Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.

There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).

In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.

This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.

Conditions

X-Linked Myotubular Myopathy

Study ID

NCT06581146

Start date

May 19, 2025

Status verified date

Aug, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 0 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
  • Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
  • Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.

Exclusion Criteria:

  • Participant is currently enrolled in an interventional study designed to treat XLMTM.

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with XLMTM

Pediatric and adolescent participants with XLMTM.

Interventions

No Intervention

No investigational drug will be administered to participants in this study.

Primary outcome measure

  • Incidence rate of cholestasis [ Time Frame: Up to Week 48 ]
  • Point prevalence of cholestasis [ Time Frame: Day 1 ]
  • Prevalence of cholestasis [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Locations

UCLA Neurological Services

Recruiting

Santa Monica, California, United States, 90401-2072

Ann & Robert H. Lurie Children's Hospital of Chicago

Recruiting

Chicago, Illinois, United States, 60611

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Cincinnati Children's Hospital Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

Children's Hospital of Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19104

UPMC Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15224

University of Utah

Recruiting

Salt Lake City, Utah, United States, 84112

Site CA15001

Recruiting

Toronto, Ontario, Canada

More Information

Sponsor

Astellas Gene Therapies

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Keywords

  • XLMTM
  • Hepatobiliary

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Astellas Gene Therapies on 2026-08-12.